IL162987A - Pharmaceutical composition comprising dunaliella powder for treating diabetes, atherosclerosis and plasma lipid levels - Google Patents

Pharmaceutical composition comprising dunaliella powder for treating diabetes, atherosclerosis and plasma lipid levels

Info

Publication number
IL162987A
IL162987A IL162987A IL16298704A IL162987A IL 162987 A IL162987 A IL 162987A IL 162987 A IL162987 A IL 162987A IL 16298704 A IL16298704 A IL 16298704A IL 162987 A IL162987 A IL 162987A
Authority
IL
Israel
Prior art keywords
atherosclerosis
powder
diabetes
donaliella
treatment
Prior art date
Application number
IL162987A
Other languages
English (en)
Hebrew (he)
Original Assignee
Nikken Sohonsha Corp
Tel Hashomer Medical Res Infrastructure & Services Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nikken Sohonsha Corp, Tel Hashomer Medical Res Infrastructure & Services Ltd filed Critical Nikken Sohonsha Corp
Publication of IL162987A publication Critical patent/IL162987A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A61K36/05—Chlorophycota or chlorophyta (green algae), e.g. Chlorella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medical Informatics (AREA)
  • Mycology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL162987A 2003-09-24 2004-07-13 Pharmaceutical composition comprising dunaliella powder for treating diabetes, atherosclerosis and plasma lipid levels IL162987A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/668,601 US7264813B2 (en) 2003-09-24 2003-09-24 Therapeutic uses of Dunaliella powder

Publications (1)

Publication Number Publication Date
IL162987A true IL162987A (en) 2013-06-27

Family

ID=34313520

Family Applications (1)

Application Number Title Priority Date Filing Date
IL162987A IL162987A (en) 2003-09-24 2004-07-13 Pharmaceutical composition comprising dunaliella powder for treating diabetes, atherosclerosis and plasma lipid levels

Country Status (5)

Country Link
US (3) US7264813B2 (https=)
EP (2) EP2269620A1 (https=)
JP (5) JP5020463B2 (https=)
AT (1) ATE548046T1 (https=)
IL (1) IL162987A (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007210917A (ja) * 2006-02-08 2007-08-23 Kochi Univ 脂肪細胞縮小化剤、医薬品及び飲食品
CA2644423A1 (en) * 2006-03-24 2007-10-04 Ian Simon Tracton Stable packaged dosage form and process therefor
JP2008222555A (ja) * 2007-03-08 2008-09-25 Nagasakiken Koritsu Daigaku Hojin アディポネクチン受容体発現増加剤
WO2009105048A2 (fr) * 2008-02-19 2009-08-27 Rached Smida Nouvelles applications du hdl reconstitué
WO2009133552A2 (en) * 2008-04-29 2009-11-05 Nikken Sohonsha Corporation Methods of treating ophthalmic disorders
US20100303989A1 (en) 2008-10-14 2010-12-02 Solazyme, Inc. Microalgal Flour
JP5733592B2 (ja) * 2008-10-20 2015-06-10 株式会社日健総本社 脂質異常治療薬の副作用防止物質
US8747834B2 (en) 2009-03-03 2014-06-10 Solazyme, Inc. Methods of treating impaired glucose metabolism via administration of algal biomass
EP2509611B1 (en) 2009-12-10 2016-03-02 Nikken Sohonsha Corporation Crude dunaliella powder for use in treating psoriasis
EP2543072B1 (en) 2010-03-02 2021-10-06 Vishay-Siliconix Structures and methods of fabricating dual gate devices
US10098371B2 (en) 2013-01-28 2018-10-16 Solazyme Roquette Nutritionals, LLC Microalgal flour
FR3009619B1 (fr) 2013-08-07 2017-12-29 Roquette Freres Compositions de biomasse de microalgues riches en proteines de qualite sensorielle optimisee
GB201718822D0 (en) 2017-11-14 2017-12-27 Univ Greenwich Production of dunaliella
JP6947665B2 (ja) * 2018-03-13 2021-10-13 アイカ工業株式会社 光硬化性粘着樹脂組成物
JP7773374B2 (ja) * 2019-04-01 2025-11-19 シェバ インパクト リミテッド 神経変性疾患、タンパク質ミスフォールディングに関連する障害及び認知機能低下の予防及び／又は治療のためのドナリエラ藻類製剤

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4199895A (en) 1977-05-25 1980-04-29 Yeda Research And Development Co. Ltd. Production of glycerol, carotenes and algae meal
USPP4511P (en) 1978-06-26 1980-03-18 Yeda Research & Development Co. Ltd. Alga strain
DE3729209A1 (de) * 1987-09-01 1989-03-09 Boehringer Mannheim Gmbh Verwendung von bezafibrat zur behandlung von diabetes
IL87260A (en) * 1988-02-25 1991-12-15 Tanaka Yoshio Encapsulated food containing dunaliella algae and its production
US5190970A (en) * 1990-10-19 1993-03-02 E. R. Squibb & Sons, Inc. Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor
US5219888A (en) 1992-03-31 1993-06-15 American Cyanamid Company Use of retinoids for the treatment of coronary artery disease
WO1993024454A1 (en) 1992-06-04 1993-12-09 Betatene Limited High cis beta-carotene composition
US6262109B1 (en) * 1995-12-22 2001-07-17 Henkel Corporation Methods of preventing and/or treating high serum levels of cholesterol and/or lipids
DK0859608T3 (da) 1995-09-18 2004-06-14 Ligand Pharm Inc Behandling af NIDDM med RXR-agonister
CA2204616C (en) * 1995-09-18 2002-12-17 Ranjan Mukherjee Ppar gamma antagonists for treating obesity
IL119224A (en) 1996-09-09 2002-11-10 Hadasit Med Res Service Medicament for protection from effects of irradiation
JP3037628B2 (ja) * 1997-03-06 2000-04-24 マイクロアルジェコーポレーション株式会社 健康補助食品用軟カプセルの製法
GB9712866D0 (en) * 1997-06-18 1997-08-20 Smithkline Beecham Plc Novel method of treatment
US6083497A (en) * 1997-11-05 2000-07-04 Geltex Pharmaceuticals, Inc. Method for treating hypercholesterolemia with unsubstituted polydiallylamine polymers
JP2002516983A (ja) 1998-03-30 2002-06-11 ザ・リージェンツ・オブ・ザ・ユニバーシティー・オブ・カリフォルニア 核受容体活性を調節するための方法及び化合物
JP2000080047A (ja) * 1998-06-30 2000-03-21 Takeda Chem Ind Ltd 医 薬
AR019727A1 (es) 1998-06-30 2002-03-13 Takeda Chemical Industries Ltd Composicion farmaceutica
IL126447A (en) * 1998-10-04 2004-09-27 Vascular Biogenics Ltd An immune preparation that confers tolerance in oral administration and its use in the prevention and / or treatment of atherosclerosis
PL348503A1 (en) * 1998-12-23 2002-05-20 Searle Llc Combinations of cholesteryl ester transfer protein inhibitors and fibric acid derivatives for cardiovascular indications
US6914073B2 (en) * 1999-03-18 2005-07-05 Bristol Myers Squibb Company Vitamin formulation for cardiovascular health
FR2795961B1 (fr) * 1999-07-09 2004-05-28 Ethypharm Lab Prod Ethiques Composition pharmaceutique contenant du fenofibrate micronise, un tensioactif et un derive cellulosique liant et procede de preparation
AU7586600A (en) 1999-09-14 2001-04-17 Ligand Pharmaceuticals Incorporated Rxr modulators with improved pharmacologic profile
US6680387B2 (en) * 2000-04-24 2004-01-20 Aryx Therapeutics Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
GB0019226D0 (en) * 2000-08-04 2000-09-27 Smithkline Beecham Plc Novel pharmaceutical
EP1430042A2 (en) 2001-09-25 2004-06-23 SmithKline Beecham Corporation Bicyclic heterocycles as rxr ligands
IN189624B (https=) * 2001-10-23 2003-03-29 Ajanta Pharma Ltd
JP3978582B2 (ja) * 2001-12-19 2007-09-19 株式会社日健総本社 カロチノイドの製造方法
US20030212138A1 (en) * 2002-01-14 2003-11-13 Pharmacia Corporation Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor

Also Published As

Publication number Publication date
US20100221348A1 (en) 2010-09-02
US7763255B2 (en) 2010-07-27
JP5020463B2 (ja) 2012-09-05
JP6321074B2 (ja) 2018-05-09
JP2013177457A (ja) 2013-09-09
JP2016147916A (ja) 2016-08-18
JP2018035200A (ja) 2018-03-08
EP1522310B1 (en) 2012-03-07
ATE548046T1 (de) 2012-03-15
HK1071845A1 (en) 2005-08-05
JP2005097255A (ja) 2005-04-14
US20050063991A1 (en) 2005-03-24
US7264813B2 (en) 2007-09-04
JP2009256392A (ja) 2009-11-05
US8343549B2 (en) 2013-01-01
EP2269620A1 (en) 2011-01-05
EP1522310A1 (en) 2005-04-13
JP5356946B2 (ja) 2013-12-04
US20080019997A1 (en) 2008-01-24
JP6490782B2 (ja) 2019-03-27

Similar Documents

Publication Publication Date Title
IL162987A (en) Pharmaceutical composition comprising dunaliella powder for treating diabetes, atherosclerosis and plasma lipid levels
WO2007008257A3 (en) Method and apparatus for delivering epinephrine
NO20080855L (no) Behandling med azetidinon-baserte kolesterol absorpsjonsinhibitorer og omega-3 fettsyrer og et kombinasjonsprodukt derav
EP1705634A4 (en) METHOD AND APPARATUS FOR COMPENSATING THE CHANGE OF A LIQUID CRYSTAL DISPLAY BY INTERVAL OF YEARS, COMPUTER PROGRAM, AND LIQUID CRYSTAL DISPLAY
EA200700924A1 (ru) Соединения ряда дибензиламина и их производные
IL184364A0 (en) Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood glp-1 level
IL185716A0 (en) Apparatus and method for computer modeling type 1 diabetes
BR112014014146A8 (pt) descarte de resíduos orgânicos
DE60114996D1 (de) Senkung des serum cholesterols
EP1624954A4 (en) PLATFORM APPARATUS, COLUMN HAVING THE APPARATUS AND METHOD OF ASSEMBLY AND USE THEREOF
MX2007007680A (es) Aparato y metodo para facilitar la transmision de particulas de vapor directamente en un pasaje nasal.
DE60316290D1 (de) Oxazolderivat und deren verwendung als insulinsensibilisatoren
杨凤 et al. The effect of garlic extract on early growth and development of Manila clam Ruditapes philippinarum
Jalali et al. Effect of laughter therapy on blood pressure patients with essential hypertension
Zieliński Characteristics of physical and chemical parameters of sewage sludge and sediments used in laboratory phytoremediation experiment
Nicholas Anti-Aging Answers
Shiozawa et al. Effect of artificial gravity with exercise load by using a short-arm centrifuge with bicycle ergometer as a countermeasure against disused osteoporosis
Prajer Spreading the Facts on Viral Diseases
Trice-Black How Mothers Perceive Their Own Sexuality.
Vanni The Effects of Digital Storytelling on Healing and Closure with World War II Veterans
Holden Payoff Transparency and Reward Desirability in the Prisoner's Dilemma
Mohseni et al. THE EFFECT OF ORAL INSULIN BASED ON SPH AND SP ON SERUM LEVELS OF GLUCOSE, INSULIN AND C-PEPTIDE IN HEALTHY VOLUNTEERS
Zheng et al. Geochemical Factors Affecting Release of U (VI) from Soils
AU2003240254A1 (en) Means for use in treating diseases correlated with or caused by non-physiological levels of microtubule-associated pp2ac
Franco González Structural and spectroscopical study of crystals of 1, 3, 4-oxadiazole derivatives at high pressure

Legal Events

Date Code Title Description
FF Patent granted
KB20 Patent renewed for 20 years